Transcatheter heart valves are used in patients suffering from medical conditions such as aortic stenosis or mitral regurgitation, where the aortic valve or the mitral valve of the heart becomes narrow and hardened due to calcium deposition, and obstructs the blood outflow from the heart, thereby making the heart work harder to pump blood.
Transcatheter heart valves are artificial heart valves inserted into the heart to keep the diseased valve open. The minimally invasive surgery involved in inserting transcatheter heart valves has made surgeons opt for it for patients who cannot undergo open heart surgery. This is expected to boost the transcatheter heart valve market in Europe during the period between 2007 and 2020.
Growing Demand for Minimally Invasive Surgeries to Help Transcatheter Heart Valve Market in Europe
It is estimated that the transcatheter heart valve market in Europe will be worth over US$2 billion by 2020. According to data released by the European Commission, in 2012, 17.9% of the population in Europe was aged 65 or above. Growing geriatric population is expected to propel the transcatheter heart valve market in Europe. The requirement of minimally invasive surgery to insert transcatheter heart valves and shorter recovery time after the surgery will make older patients prefer it over traditional open heart surgeries.
Transcatheter Mitral Valves Still to Get Widely Accepted in Europe
On the basis of product type, the transcatheter heart valve market has been segmented into transcatheter aortic valves and transcatheter mitral valves. In transcatheter aortic valve implantation (TAVI), the device is introduced into the body by creating a small incision in the artery that carries blood to the leg. Through the opening, the catheter is pushed through the blood vessels to reach the damaged aortic valve. Once the new transcatheter aortic valve is in place, it helps the blood flow properly without straining the heart excessively.
Mitral regurgitation (MR) is a common heart disease in Europe, in which the mitral valve of the heart either becomes hardened or too loose. Treatment of a degenerative mitral valve requires surgical intervention, which involves replacement or removal of the valve. During the past few years, transcatheter mitral valves have been developed to repair the valve through minimally invasive surgeries. However, the effectiveness of transcatheter mitral valve replacement (TMVR) is still being tested through clinical trials and hence has not been yet approved in Europe.
Italy and Germany to Contribute Significantly towards Growth of Transcatheter Heart Valve Market in Europe
France, Germany, Italy, Spain, and the UK are the major markets for transcatheter heart valves in Europe. According to Eurostat, in 2012, among the European Union member states, Italy and Germany had the highest population of people in the age group of 65 and above. The growth of the transcatheter heart valve market will be boosted by the increased demand from these countries during the next couple of years.
Browse the full Europe Transcatheter Heart Valve Market report at http://www.mrrse.com/market-snapshot
Key Players in Transcatheter Heart Valve Market in Europe
Some of the key players in the transcatheter heart valve market in Europe are Edwards Lifesciences, Medtronic, and Boston Scientific. Notable devices manufactured by the key players such as SAPIEN XT transcatheter heart valve developed by Edwards Lifesciences has been accepted well by the patients.